CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia

Leukemia

Volumn 25, Issue 5, 2011, Pages 792-799

  Coles, S J ^a   Wang, E C Y ^a   Man, S ^a   Hills, R K ^a   Burnett, A K ^a   Tonks, A ^a   Darley, R L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

AML; CD200; CD200R; immunity; immunosuppression; natural killer cell

Indexed keywords

CD16 ANTIGEN; CD200 ANTIGEN; CD56 ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL ACTIVITY; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNOREGULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD; BLAST CRISIS; CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE;

EID: 79955847224     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.1     Document Type: Article

References (46)

1. Barclay AN, Clark MJ, McCaughan GW. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immuno-globulin superfamily with a light-chain-like structure. Biochem Soc Symp 1986; 51: 149-157.
2. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002; 23: 285-290. (Pubitemid 34628770)
3. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH et al. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 2000; 13: 233-242.
4. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000; 290: 1768-1771. (Pubitemid 32004808)
5. Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation 2005; 79: 488-491. (Pubitemid 40280183)
6. Gorczynski L, Chen Z, Hu J, Kai Y, Lei J, Ramakrishna V et al. Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells. J Immunol 1999; 162: 774-781. (Pubitemid 29035399)
7. Moreaux J, Veyrune JL, Reme T, De VJ, Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 2008; 366: 117-122. (Pubitemid 350297222)
8. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 2008; 57: 987-996.
9. Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 2007; 21: 2495-2505. (Pubitemid 350148893)
10. Wong KK, Khatri I, Shaha S, Spaner DE, Gorczynski RM. The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol 2010; 88: 361-372.
11. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007; 178: 5595-5605. (Pubitemid 46674355)
12. Brunetti L, Di NR, Abate G, Gorrese M, Gravetti A, Raia M et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol 2009; 145: 665-667.
13. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006; 108: 4194-4197. (Pubitemid 44913292)
14. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007; 21: 566-568.
15. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 2007; 364: 778-782. (Pubitemid 350103695)
16. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol 2008; 29: 464-468.
17. Gorczynski RM, Chen Z, Hu J, Kai Y, Lei J. Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. Clin Exp Immunol 2001; 126: 220-229. (Pubitemid 32995135)
18. Gorczynski RM. Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages. Eur J Immunol 2001; 31: 2331-2337. (Pubitemid 32785351)
19. Zhang L, Stanford M, Liu J, Barrett C, Jiang L, Barclay AN et al. Inhibition of macrophage activation by the myxoma virus M141 protein (vCD200). J Virol 2009; 83: 9602-9607.
20. Cooper MA, Caligiuri MA. Immunologic manipulation in AML: from bench to bedside. Leukemia 2002; 16: 736-737. (Pubitemid 34449757)
21. Guinn BA, Mohamedali A, Thomas NS, Mills KI. Immunotherapy of myeloid leukaemia. Cancer Immunol Immunother 2007; 56: 943-957. (Pubitemid 46675306)
22. Barrett AJ, Le BK. Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol 2010; 161: 223-232.
23. Warren HS, Smyth MJ. NK cells and apoptosis. Immunol Cell Biol 1999; 77: 64-75. (Pubitemid 29111593)
24. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors 2010; 36: 274-288.
25. Moretta L, Biassoni R, Bottino C, Cantoni C, Pende D, Mingari MC et al. Human NK cells and their receptors. Microbes Infect 2002; 4: 1539-1544. (Pubitemid 36050823)
26. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009; 119: 1251-1263.
27. Hecht ML, Rosental B, Horlacher T, Hershkovitz O, De Paz JL, Noti C et al. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res 2009; 8: 712-720.
28. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002; 117: 821-827. (Pubitemid 34639242)
29. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99: 3661-3667. (Pubitemid 34534536)
30. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 2009; 126: 458-465.
31. Lennon G, Auffray C, Polymeropoulos M, Soares MB. The I.M.A.G.E. consortium: an integrated molecular analysis of genomes and their expression. Genomics 1996; 33: 151-152.
32. Grignani F, Kinsella T, Mencarelli A, Valtieri M, Riganelli D, Grignani F et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 1998; 58: 14-19. (Pubitemid 28027708)
33. Derby E, Reddy V, Baseler M, Malyguine A. Flow cytometric assay for the simultaneous analysis of cell-mediated cytotoxicity and effector cell phenotype. Biotechniques 2001; 31: 660, 664-665.
34. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007; 109: 323-330. (Pubitemid 46053073)
35. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008; 27: 5932-5943.
36. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105: 3615-3622. (Pubitemid 40628208)
37. Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 2005; 19: 2215-2222. (Pubitemid 41741617)
38. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640. (Pubitemid 33043908)
39. Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005; 106: 1711-1717. (Pubitemid 41208585)
40. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 15-22. (Pubitemid 39626587)
41. Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E et al. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 2005; 19: 835-840. (Pubitemid 40663105)
42. Zimmer J, Andres E, Hentges F. NK cell subsets and CD107a mobilization assay. Leukemia 2005; 19: 1849-1851.
43. Derby EG, Reddy V, Nelson EL, Kopp WC, Baseler MW, Dawson JR et al. Correlation of human CD56+ cell cytotoxicity and IFN-gamma production. Cytokine 2001; 13: 85-90. (Pubitemid 32579313)
44. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97: 3146-3151.
45. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008; 180: 699-705.
46. Pallasch CP, Ulbrich S, Brinker R, Hallek M, Uger RA, Wendtner CM. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res 2009; 33: 460-464.